Spirit Scientific Co (7790.TWO) Stock Price

Spirit Scientific Co Ltd generates revenue through autologous Platelet Lyophilized Technology (PLT) cryo-crystal preparation services and autologous high-concentration platelet gel preparation services. The company also offers clinical research cooperation commission services, blood-related commissioned manufacturing, biomaterial-type cryo-crystal testing or commissioned manufacturing, biomaterial-type cosmetic raw material production, and biomaterial-type cryo-crystal laboratory construction consulting services. These services are primarily sold to healthcare providers and research institutions within Taiwan, focusing on biomaterial separation, purification, mass production, and standardized process development for biotechnology applications. The firm's main products target the health care equipment and supplies industry, with a strong emphasis on growth factor cryo-crystal related solutions. Their services are tailored to meet the needs of clients seeking advanced biotechnology services, including the development of biomaterial-type cryo-crystals and cosmetic raw materials. Spirit Scientific operates exclusively in Taiwan, serving local healthcare and research sectors with specialized biotechnology offerings. Revenue streams include both service-based contracts for cryo-crystal preparation and manufacturing, as well as consulting services for laboratory construction. The company’s focus on biomaterial separation, purification, and dosage form improvement drives demand from clients requiring standardized biotechnology processes. All services are delivered within Taiwan, aligning with the firm's exclusive market presence.